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open access aThe development of an antibody in people with hemophilia to products used in the treatment and
prevention of bleeding, also referred to as an inhibitor, is the most serious complication of
hemophilia care today. CDC, together with healthcare providers, consumer organizations,
hemophilia organizations, and federal partners, has developed a public health agenda to prevent
the development of inhibitors. This paper describes a public health approach that combines a
national surveillance program with epidemiologic, laboratory, and prevention research to address
knowledge gaps in rates and risk factors for inhibitor development, and in knowledge and behaviors
of patients and providers, in addition to screening and treatment practices.
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionThe primary congenital bleeding disorders arehemophilia A and B, which are deﬁciencies in aprotein (factor) that is necessary for normal blood
clotting, and affect approximately 1 in 10,000 and 1 in
35,000 male Americans, respectively.1 As many as one third
of patients with severe hemophilia A will develop an
antibody (i.e., inhibitor) to the factor replacement products
that are infused intravenously to stop or prevent a bleeding
episode.2 Most inhibitors develop during the ﬁrst few
infusions with factor, which, among those with severe
hemophilia, usually occur before age 2 years although all
patients are at risk of developing an inhibitor.3 An inhibitor
neutralizes a treatment product’s ability to control bleeding.
The healthcare costs associated with inhibitors are
staggering. Patients with inhibitors are twice as likely to
be hospitalized for a bleeding complication.4 In addition,
compared with the cost of care for patients without an
inhibitor, the cost of care for those with an inhibitor who
have a bleeding complication is four to ﬁve times greaterision of Blood Disorders (Soucie, Miller, Kelly, Oakley),
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Improvements in clotting factor safety and efﬁcacy
over the past several decades, along with the widespread
use of prophylaxis, have greatly decreased hemophilia-
related morbidity and mortality. Prophylactic therapy
(infusion of factor products to prevent bleeding episodes) is
considered the standard of care for patients who do not
have an inhibitor, and primary prophylaxis (i.e., therapy
started before the second clinically evident large joint bleed
and age 3 years) has been shown to decrease frequency of
hemarthroses and prevent long-term joint damage.7
Although these advancements in care and treatment
have, in many cases, led to a nearly bleed-free life, this is
not true for patients with an inhibitor, who continue to
have bleeding episodes that require frequent and costly
treatment and often take longer to resolve and, therefore,
have a greater potential effect on quality of life owing to
missed days at school or work.
Patients with an inhibitor have signiﬁcant care man-
agement considerations beyond those without an inhib-
itor. Because there are fewer factor replacement choices
for patients with an inhibitor, medical management often
is more complex. Treatment for the inhibitor can include
use of more expensive inhibitor-bypassing drugs or
immune tolerance induction (ITI) therapy, which
requires frequent infusion of large doses of factor
products. Venous access can become difﬁcult and may
require the use of venous access devices, arteriovenous
ﬁstulas, or both.
Surgical intervention often is more complex, given
limited access to surgeons with experience operating onMedicine. This is an
mmons.org/licenses/by-nc-nd/3.0/).
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additional ﬁnancial burden, as well as difﬁculty navigat-
ing insurance options and management. Even with
treatment, patients with an inhibitor are signiﬁcantly
more likely to die from bleeding complications than
those without an inhibitor.8
The purpose of this paper is to describe a public health
approach that combines a national surveillance program
with epidemiologic, laboratory, and prevention research
to address knowledge gaps in the epidemiology and
prevention of inhibitors in the U.S.
Causes of Inhibitors
Inhibitors are antibodies developed by the body’s
immune system in response to an infused replacement
factor. Although genetic factors, such as the F8 or F9 gene
mutation and polymorphisms within certain immune
system genes, are known to inﬂuence the risk of devel-
oping an inhibitor,9 environmental and treatment factors
also can play a role.
For example, a cohort study10 of previously untreated
patients with hemophilia followed for the ﬁrst 75
exposure days at 26 European treatment centers observed
that periods of “intense treatments” (in which factor
replacement was given for 5 or more contiguous days)
were more likely to lead to inhibitor development.
Further study of other treatment-related risk factors such
as product switching, continuous factor infusion, infec-
tions, and surgical or non-surgical procedures is neces-
sary for development of better prevention strategies.
National Surveillance for Inhibitors
Hemophilia is a rare condition, affecting an estimated
22,000 male Americans. Although as many as one third
of these patients might develop an inhibitor at some
point, in any given year the number of new inhibitor
cases is relatively small. Surveillance from the United
Kingdom has found an overall incidence rate of inhibitor
development among patients with severe hemophilia of
10.92 per 1,000 person-years.11
Therefore, monitoring of a large proportion of the U.S.
population with hemophilia will be necessary to obtain
accurate measures of incidence and prevalence, effec-
tively monitor trends in occurrence rates over time, and
assess risk factors for developing inhibitors. Monitoring
large numbers of patients also will be required to
determine whether apparent clusters of inhibitor cases
represent an actual increase that might be caused by
something preventable or are just due to chance.
National surveillance with centralized testing for inhib-
itors can provide other advantages over individual local,regional, or multisite efforts, including standardized
inhibitor screening tests administered on a regular basis,
conﬁrmation of local inhibitor testing results, and con-
sistent monitoring and reporting of national inhibitor
occurrence rates.
The Role of the U.S. Hemophilia Treatment
Center Network
In the early 1970s, the development of clotting factor
concentrates that were effective at stopping bleeding
episodes and could be administered to patients outside
of a hospital setting led the U.S. Government to establish
a network of specialized hemophilia treatment centers
(HTCs) in 1975 in order to provide multidisciplinary
care to patients with hemophilia.12 A population-based
study1 in the 1990s showed that about 70% of the U.S.
population with hemophilia was receiving care in these
centers. Furthermore, the study showed that rates of both
mortality and hospitalization for bleeding complications
were lower among those receiving care in the HTCs than
among those receiving care elsewhere.4,13
In 1998, CDC established a surveillance system in the
HTCs to monitor care practices and patient outcomes,
including monitoring for product-transmitted infec-
tions.14,15 Although the system was not speciﬁcally
designed to study inhibitors, analysis of data from the
surveillance system revealed that less than one half of
patients were being screened regularly for inhibitors
(JMS, unpublished observations, 2013).
Because the patient and provider communities have
identiﬁed inhibitors as an issue of concern, CDC has
begun national surveillance for inhibitors in the HTCs,
with the CDC Division of Blood Disorders laboratory
providing prospective inhibitor testing using methods
developed as part of a research study supported by public
and private funding3,16 and the HTCs providing clinical
expertise and data to characterize risk factors for
inhibitor development.
Identiﬁcation of risk factors for the development of
inhibitors is necessary to avoid practices that can increase
the likelihood of inhibitor development. Anecdotal
reports and a single-institution case series have suggested
that early prophylaxis begun in the ﬁrst year of life and
prior to the ﬁrst joint bleed lowers the risk of inhibitor
development.17 Avoidance of treatment with factor VIII
(FVIII) replacement therapy coincident with vaccine
administration has been recommended by some in order
to avoid a theoretic “danger signal” that might trigger an
immune response after FVIII exposure.17,18
Although most inhibitors appear before the ﬁrst 50
treatments with factor replacement (exposure days),
clinical trials that enrolled patients with more than 150www.ajpmonline.org
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inhibitors might develop well beyond the ﬁrst 50
exposure days.19 The calculated risk of inhibitor for-
mation after 150 exposure days, based on a systematic
review of 33 different studies, was estimated to be
approximately 3 per 1,000 person-years.19
Rarely, new inhibitors have been linked to speciﬁc
factor-replacement products, and this discovery has led
to a better appreciation of possible alterations of the
FVIII protein that render it more immunogenic.20 The
role of speciﬁc treatment products is very difﬁcult to
determine even when utilizing meta-analyses, because
the studies use different patient populations and fre-
quencies of inhibitor testing. Better precision from
prospective monitoring will help to establish a “standard
risk,” to which the risk of new products undergoing
evaluation for safety in clinical trials can be compared.
Many patients are reluctant to switch treatment products
because of a realistic fear that a new inhibitor might
emerge; however, better risk stratiﬁcation will help to
inform their decisions.
Inhibitors that result from a very strong immune
response, called high-titer inhibitors, necessitate a change
in treatment product and regimen, whereas low-titer
inhibitors can be overcome by increasing the dose of
FVIII. In some cases, low-titer inhibitors can be transient
and disappear without change in treatment. Cross-
sectional studies will not detect the majority of the
transient inhibitors, and even if they are detected, it is
unlikely that such an inhibitor would be correctly
categorized as self-resolving.
Patients with mild hemophilia have a lower risk of
inhibitor formation. However, because their exposures to
treatment products more frequently are associated with
surgeries, an unrecognized inhibitor could have cata-
strophic outcomes. Once factor replacement treatment is
discontinued, inhibitors might become low titer or not
detectable, which could lead to an underestimation of
inhibitors among patients with mild hemophilia in cross-
sectional studies or in prospective studies with very short
follow-up periods. Therefore, long-term prospective
monitoring can better assess the occurrence and clinical
signiﬁcance of inhibitors among those with mild
hemophilia.
A component of the national inhibitor surveillance will
be the retrospective data collection on genetic and
environmental treatment–related risk factors in the
previous 4-month period at the time of new inhibitor
identiﬁcation. Although retrospective data have limita-
tions, collecting these data (including factor infusion
logs) from all patients prospectively is not feasible given
the high costs of HTC staff time for the follow-up
required to ensure patient adherence to reporting.3November 2014A partnership combining the clinical expertise of the
HTCs and the epidemiologic and laboratory skills of
CDC is ideal for mounting an effective national surveil-
lance program of and collecting data on treatment-
related risk factors for a large American cohort to identify
which treatment practices are associated with a greater
likelihood of inhibitor development and, therefore,
should be avoided.
The Role of a Central Laboratory
Inhibitors occurring among patients are measured by
their ability to inhibit factor activity in vitro. Measure-
ment of hemophilic inhibitors in the U.S. was stand-
ardized in 1975 at a meeting in Bethesda MD, which
produced a method bearing the name of the conference
site.21 The Bethesda assay method has persisted virtually
unchanged in the majority of laboratories in the U.S.
Modiﬁcations to the method—called the Nijmegen–
Bethesda assay and recommended by the International
Society on Thrombosis and Haemostasis—were intro-
duced in Europe in 199522,23 but have not been adopted
widely in the U.S.24
The United Kingdom and European Union inhibitor
surveillance programs rely on test results reported from
local laboratories; however, proﬁciency testing has shown
a high degree of inter-laboratory variability in results of
inhibitor tests in Europe,25 the United Kingdom,26 and
the U.S.,24 which could lead to inconsistencies in the
collected data. Regulatory bodies have recommended
either centralized testing for inhibitors or quality control
systems to monitor local laboratories as part of national
registries,27 and CDC has concluded that centralized
testing is needed initially to provide the degree of
standardization required to accurately assess the preva-
lence and incidence of inhibitors in the U.S. hemophilia
population.3
The performance of large numbers of tests by a central
laboratory, as piloted by CDC,3 will result in economies
of scale, enhanced quality control, and the availability of
large data sets for analysis. Reagents, such as buffered
normal pooled plasma, can be prepared or purchased in
bulk. Quality control testing materials, which are not
available commercially, can be prepared and used con-
sistently. Analysis of large data sets has led to the
recognition of systematic testing problems and develop-
ment of improvements in methods used for inhibitor
measurement.16,28
Validation of a modiﬁcation to the Nijmegen–
Bethesda assay for removing infused FVIII prior to
inhibitor measurement has facilitated surveillance by
allowing patients on prophylaxis and those recently
treated to be tested without refraining from factor
Soucie et al / Am J Prev Med 2014;47(5):669–673672use.16 The ability to test for an inhibitor in the presence
of FVIII has the potential to facilitate more complete
monitoring of the hemophilia population for inhibitors.
Study of large numbers of patients with a single method
has allowed development of a more accurate deﬁnition of
a positive inhibitor result and the addition of more
sensitive and speciﬁc assays to conﬁrm questionable
results.28
Although standardized methods are crucial for sur-
veillance purposes, they also are important for clinical
care to allow early detection of inhibitors and monitor-
ing of therapy, such as ITI. Technical advances in
inhibitor measurement developed at CDC will be
disseminated to local laboratories used by providers of
care to patients with hemophilia. This process will be
monitored by veriﬁcation of local laboratory testing
results by repeat testing of samples at the CDC
laboratory. It is expected that dissemination of the
standardized testing methods to local laboratories will
increase the accuracy and efﬁciency of case-ﬁnding
activities in the future and will facilitate the transition
of the role of the CDC laboratory from the performance
of centralized testing to serving as a reference laboratory
for monitoring and quality control.
The Contribution of Public Health Research
to Inhibitor Prevention
The public health goal of inhibitor surveillance and
research is to reduce the incidence of inhibitors. In the
U.S., surveillance with centralized testing will determine
the magnitude of this adverse event through measure-
ment of the incidence and prevalence of inhibitor
development among patients. Inhibitor research is
needed to characterize inhibitor testing among current
providers, describe inhibitor characteristics and clinical
outcomes, identify key genetic and environmental risk
factors, and determine patient health information needs
regarding inhibitors.
Public health research is needed in the U.S. to
identify standardized, evidence-based intervals for
inhibitor testing. Early identiﬁcation of inhibitors has
been correlated with increased treatment success and
decreased duration of inhibitor treatment.29 Studies
are needed to characterize provider testing practices
and determine the ways in which knowledge and
awareness of inhibitors can inﬂuence testing practices.
Assessment of the barriers and facilitators to routine
inhibitor screening will inform the development of
interventions.
Public health laboratory research is needed to (1)
characterize inhibitor titer levels over time; (2) inves-
tigate inhibitor characteristics, such as reactions withspeciﬁc products, epitope speciﬁcity, and kinetics; and (3)
correlate these characteristics with clinical outcomes,
including inhibitor transience and response to ITI
therapy. Data from these studies will be used to generate
evidence-based, standardized deﬁnitions of both transi-
ent and clinically signiﬁcant inhibitors that, in turn, will
allow clinicians to provide more rapid and appropriate
treatment.
Epidemiologic studies are needed to further eluci-
date the risks and protective factors for inhibitor
development. Surveillance efforts will facilitate
research efforts by providing access to the necessary
large sample sizes required to examine patient immune
response variations, product exposure risks, and
potential protective factors for inhibitor development.
The results of studies of the interactions between these
genetic and environmental risk factors then can be
used to develop patient-speciﬁc risk algorithms for
inhibitor development.
Prevention research is needed to assess the health
information needs of patients with and at risk for
inhibitors and to develop interventions. Despite the fact
that inhibitors have been identiﬁed as a priority issue by
the hemophilia community, no studies have examined
patient knowledge and awareness of inhibitors; experi-
ences with testing, diagnosis, and treatment; and barriers
and facilitators to testing and treatment. Such research is
needed to develop, implement, and evaluate interven-
tions to address these issues. Gaps in knowledge among
patients can negatively inﬂuence participation in needed
research studies in the short term and can decrease the
effectiveness of future inhibitor reduction strategies in
the long term.
Finally, research is needed to assess the full economic
effect of inhibitor development in the U.S. Current
research has demonstrated that the cost to treat a single
inhibitor patient can exceed 1 million dollars per year.5,6
However, little research has been done in the U.S. to
document the direct inpatient, direct outpatient, and
indirect costs associated with care for patients with
inhibitors. The results of such research will be needed
to evaluate the cost-effectiveness of future interven-
tions and inform policy decisions regarding resource
allocation.Conclusions
Inhibitor development is currently one of the most
important causes of morbidity for patients with hemo-
philia in the U.S. Prevention will require a comprehen-
sive public health approach that includes not only
surveillance, but epidemiologic, laboratory, and preven-
tion research. Partnerships with the HTCs, consumerwww.ajpmonline.org
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partners are vital to accomplishing CDC’s public health
goal of preventing inhibitor development.
The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the ofﬁcial position of
CDC.
No ﬁnancial disclosures were reported by the authors of
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